CD38-CS1 CAR-T cells

· The Second Hospital of Shandong University

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CD38-CS1 CAR-T cells, covering 2024-08-28 to 2024-08-28. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Study of CD38\CS1 Chimeric Antigen Receptor T Cells in the Treatment of Refractory/Recurrent Multiple Myeloma [EARLY_Phase 1]

See pricing